Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Stein

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Australian Family Physician|October 6, 2007
Vitamin D deficiencyMark Stein
The Lancet. Psychiatry|August 12, 2018
Refining treatment choices for ADHDAnne Arnett, Mark Stein
The Canadian Journal of Urology|March 1, 1997
Meta-analysis of four different surgical treatments for stress urinary incontinenceScott Serels, Mark Stein
Journal of the American Academy of Child and Adolescent Psychiatry|September 22, 2005
ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label studyTimothy Wilens, Keith McBurnett, Mark Stein, et al.
Cancers|October 13, 2021
Overcoming Immune Resistance in Prostate Cancer: Challenges and AdvancesMiyad Movassaghi, Rainjade Chung, Christopher B Anderson, et al.
Oncotarget|June 4, 2015
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cellsNitu Bansal, Prasun J Mishra, Mark Stein, et al.
Cancer|June 19, 2009
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology GroupRobert Dreicer, Hailun Li, Mark Stein, et al.
Journal of Child and Adolescent Psychopharmacology|June 14, 2006
Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorderJames J McGough, Keith McBurnett, Oscar Bukstein, et al.
Immunotherapy|December 21, 2021
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseasesRichard L Wasserman, Sudhir Gupta, Mark Stein, et al.
Journal of Attention Disorders|September 18, 2012
Future research directions in sleep and ADHD: report of a consensus working groupJudith Owens, Reut Gruber, Thomas Brown, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Australian Family Physician|October 6, 2007
Vitamin D deficiencyMark Stein
The Lancet. Psychiatry|August 12, 2018
Refining treatment choices for ADHDAnne Arnett, Mark Stein
The Canadian Journal of Urology|March 1, 1997
Meta-analysis of four different surgical treatments for stress urinary incontinenceScott Serels, Mark Stein
Journal of the American Academy of Child and Adolescent Psychiatry|September 22, 2005
ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label studyTimothy Wilens, Keith McBurnett, Mark Stein, et al.
Cancers|October 13, 2021
Overcoming Immune Resistance in Prostate Cancer: Challenges and AdvancesMiyad Movassaghi, Rainjade Chung, Christopher B Anderson, et al.
Oncotarget|June 4, 2015
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cellsNitu Bansal, Prasun J Mishra, Mark Stein, et al.
Cancer|June 19, 2009
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology GroupRobert Dreicer, Hailun Li, Mark Stein, et al.
Journal of Child and Adolescent Psychopharmacology|June 14, 2006
Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorderJames J McGough, Keith McBurnett, Oscar Bukstein, et al.
Immunotherapy|December 21, 2021
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseasesRichard L Wasserman, Sudhir Gupta, Mark Stein, et al.
Journal of Attention Disorders|September 18, 2012
Future research directions in sleep and ADHD: report of a consensus working groupJudith Owens, Reut Gruber, Thomas Brown, et al.
Pageof 7